![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Jebaraj Billy Michael Chelliah
Publisher: Informa Healthcare
ISSN: 1042-8194
Source: Leukemia and Lymphoma, Vol.54, Iss.6, 2013-06, pp. : 1177-1182
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Alemtuzumab in chronic lymphocytic leukemia
By James Danelle F Kipps Thomas J
Future Oncology, Vol. 3, Iss. 1, 2007-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Andritsos Leslie Khoury Hanna
Current Treatment Options in Oncology, Vol. 3, Iss. 3, 2002-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Recent Advances in Chronic Lymphocytic Leukemia
By Abbott Brian
Cancer Investigation, Vol. 24, Iss. 3, 2006-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
New Therapies for Chronic Lymphocytic Leukemia
Current Cancer Therapy Reviews, Vol. 9, Iss. 4, 2013-11 ,pp. :